Wayne Koberstein

  1. Companies To Watch: Neurana 4/1/2020

    This 10-person startup in San Diego is aiming for muscle-spasm relief without sedation in a purified drug.

  2. A New Life In Bio 2/28/2020

    This unlikely CEO’s experience offers some valuable lessons in founding and scaling up a biotech company, particularly one in a nascent space such as regenerative medicine.

  3. Companies To Watch: Adaptive Phage Therapeutics 2/28/2020

    Adaptive Phage Therapeutics has created a large catalog of bacteria-killing viruses combined with a diagnostic test to identify and target specific bacterial strains infecting individual patients.

  4. Companies To Watch: Imago BioSciences 1/31/2020

    In developing a new drug for MPN diseases, Imago is entering a space where two potential competitors, Jakafi and Inrebic, both JAK (janus associated kinase) inhibitors, are already on the market.

  5. A Global Biotech Player From Down Under 1/31/2020

    “The other part of being a CEO of a listed company is all about investors, and that was an uphill learning curve for me because I’d never dealt with that aspect,” explains Imugene’s CEO Leslie Chong.

  6. Companies To Watch: Scynexis 12/30/2019

    Scynexis is creating multiple development programs and a new class of antifungals — all in a single, and singular, drug.

  7. Competing Interests Complicate FDA Reform 11/27/2019

    With input from two long-time observers of the biopharma industry and its U.S. regulator, this article covers a cross-section of opinions regarding trends and proposals for improving the FDA review process.

  8. Companies To Watch: Obsidian Therapeutics 11/1/2019

    Obsidian Therapeutics targets gene and cell therapies with a technology designed to control the production and activity of therapeutic proteins those therapies induce.

  9. Crossing Over From Supplier To Sponsor 11/1/2019

    What can make a company decide to enter new therapeutic entities into clinical development after decades as a dedicated supplier to bio research labs? Here we explain the reasons and implications of ArunA Bio’s decision.

  10. Taking It All The Way To Phase 3 Clinical Trials 11/1/2019

    Pluristem offers one example of how a new company in drug development can build the needed infrastructure to maintain its independence as a sponsor.